Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Duisburg – page 37

1 741 clinical trials in Duisburg, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Duisburg at a glance
1 741
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 741 trials in Duisburg

Open in trial search

Thalassaemia

Recruiting

Study on the Safety and Effectiveness of CTX001 for Children with Transfusion-Dependent Beta-Thalassemia Using Exagamglogene Autotemcel and a Drug Combination

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Busulfan
  • Sponsor:Vertex Pharmaceuticals Inc.

Study on Elacestrant and Everolimus for Patients with Advanced ER+/HER2- Breast Cancer Resistant to Endocrine Therapy and CDK4/6 Inhibitors

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Elacestrant
  • Sponsor:Medica Scientia Innovation Research S.L.

Thermal burn

Recruiting

Study on the Effectiveness of EHSG-KF Skin Graft for Patients with Deep Partial and Full-Thickness Burns

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bilayer Engineered Collagen Hydrogel-Based Skin Graft Composed Of Autologous Keratinocytes And Fibroblasts
  • Sponsor:Cutiss AG

Study of GBT021601 for Adults and Children with Sickle Cell Disease

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Osivelotor
  • Sponsor:Global Blood Therapeutics Inc.

Study on the Safety and Effectiveness of Isatuximab and Drug Combination for Adults with Relapsed or Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Goethe University Frankfurt

Leukaemia

Recruiting

Study on the Safety and Effectiveness of Venetoclax with Fludarabine, Amsacrine, and Cytarabine for Patients with MDS, CMML, or Secondary AML Undergoing Stem Cell Transplantation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Allopurinol
  • Sponsor:Heinrich-Heine-Universitaet Duesseldorf

Study of Efgartigimod PH20 SC for Children Aged 2 to 17 with Generalized Myasthenia Gravis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Study on Preventing Blood Clots in Patients with New-Onset Post-Operative Atrial Fibrillation after CABG Using Apixaban and Drug Combination

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Icahn School Of Medicine At Mount Sinai

Study of accelerated chemoradiotherapy followed by durvalumab treatment in patients with locally advanced non-small-cell lung cancer (NSCLC) using PET imaging guidance

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:TheraOp gGmbH

Study comparing prophylactic versus selective surfactant (poractant alfa, phospholipid fraction) administration in preterm infants with respiratory distress syndrome aged 25-30 weeks

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Poractant Alfa
  • Sponsor:Universitaetsklinikum Schleswig-Holstein AöR

Long-Term Safety Study of Dabrafenib Mesylate and Trametinib Dimethyl Sulfoxide for Patients Benefiting from Previous Treatment in Multiple Indications

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Dabrafenib Mesylate
  • Sponsor:Novartis Pharma AG

Study on the Effect of Durvalumab and Tremelimumab with Radioactive Glass Spheres in Patients with Non-Resectable Liver Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Klinikum Der Universitat Munchen AöR

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Duisburg

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on prostate cancer, bladder cancer, and lung cancer treatments. Studies evaluate novel therapeutic combinations and targeted approaches for improved patient outcomes.

  • Metastatic prostate cancer therapies
  • Non-muscle invasive bladder cancer treatments
  • Small cell lung cancer interventions

Multiple studies exploring immunotherapy combinations and targeted molecular approaches.

02 Hematological Disorders

Research focusing on blood disorders including multiple myeloma, acute leukemia, and Von Willebrand Disease. Studies evaluate novel treatment combinations and targeted therapies.

  • Innovative myeloma treatments
  • Leukemia therapeutic strategies
  • Blood disorder management

Emphasis on improving treatment outcomes and patient quality of life.

03 Chronic Conditions

Clinical trials investigating treatments for diabetes, asthma, and Crohn's disease. Research focuses on new therapeutic approaches and disease management strategies.

  • Type 1 diabetes interventions
  • Respiratory disease management
  • Gastrointestinal disorders

Studies aim to enhance treatment efficacy and patient care standards.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.